FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

Dateline City:

KENILWORTH, N.J.

Application Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival for Patients Taking KEYTRUDA Compared to Chemotherapy in Patients with PD-L1 Expression on One Percent or More of the Cancer Cells

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review a new supplemental Biologics License Application
(sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy, to include data from KEYNOTE-010.
Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]orKim Hamilton, [phone]orInvestor:Teri Loxam, (908) 740-1986orJustin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Corporate News - March 7, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda NYSE:MRK Source Type: news